Our top pick for
DURECT Corporation is a drug manufacturers-specialty & generic business based in the US. DURECT Corporation shares (DRRX) are listed on the NASDAQ and all prices are listed in US Dollars. DURECT Corporation employs 95 staff and has a trailing 12-month revenue of around USD$42 million.
|Latest market close||USD$1.98|
|52-week range||USD$0.9502 - USD$3.949|
|50-day moving average||USD$1.9285|
|200-day moving average||USD$1.9974|
|Wall St. target price||USD$6.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.151|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||-6.60%|
|1 month (2020-12-18)||-13.54%|
|3 months (2020-10-19)||9.39%|
|6 months (2020-07-17)||-9.59%|
|1 year (2020-01-17)||-21.12%|
|2 years (2019-01-18)||241.38%|
|3 years (2018-01-19)||65.00%|
|5 years (2016-01-19)||69.23%|
|Revenue TTM||USD$42 million|
|Gross profit TTM||USD$-5,288,000|
|Return on assets TTM||-6.07%|
|Return on equity TTM||-32.35%|
|Market capitalisation||USD$436.8 million|
TTM: trailing 12 months
There are currently 8.8 million DURECT Corporation shares held short by investors – that's known as DURECT Corporation's "short interest". This figure is 4.4% down from 9.2 million last month.
There are a few different ways that this level of interest in shorting DURECT Corporation shares can be evaluated.
DURECT Corporation's "short interest ratio" (SIR) is the quantity of DURECT Corporation shares currently shorted divided by the average quantity of DURECT Corporation shares traded daily (recently around 766742.58456201). DURECT Corporation's SIR currently stands at 11.53. In other words for every 100,000 DURECT Corporation shares traded daily on the market, roughly 11530 shares are currently held short.
However DURECT Corporation's short interest can also be evaluated against the total number of DURECT Corporation shares, or, against the total number of tradable DURECT Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DURECT Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DURECT Corporation shares in existence, roughly 40 shares are currently held short) or 0.0499% of the tradable shares (for every 100,000 tradable DURECT Corporation shares, roughly 50 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against DURECT Corporation.
Find out more about how you can short DURECT Corporation stock.
We're not expecting DURECT Corporation to pay a dividend over the next 12 months.
Over the last 12 months, DURECT Corporation's shares have ranged in value from as little as $0.9502 up to $3.949. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DURECT Corporation's is 1.7575. This would suggest that DURECT Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; Gilead Sciences, Inc; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.